Google Search

Search

Already a Member ?

Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Drug Intermediates, Speciality Chemicals, Raw Materials, Fine and Specialty Chemicals Intermediates, Pharmaceutical Bulk Drugs

Indian drugs and pharmaceutical industry has advanced perceptibly and is getting ready  for the new patent regime and  to withstand global competition, which is expected to be unleashed by new winds of liberalisation - a new era of liberalisation - much different from what was ushered in since the conclusion of the Uruguay Round and the establishment of the World Trade Organisation.

The industry has been expanding at annual rates ranging between 8 to 10% (against global growth rate of 6%).  According to a study  by McKinsey, Vision 2010, the domestic pharmaceutical industry could attain a size of  $25 billion (Rs 1200 billion) by 2010 by focusing on two areas: first, innovation-led research, development and new drug discoveries; and second, information technology-led remote sales and marketing.  The market for bulk drugs and formulations had increased from about Rs 103  billion in 1990-91 to an estimated Rs 435  billion at the end of 2003-04.  The prices of Indian essential drugs are among the lowest in the world. Apart from strides made by the industry in the last half-a-century, lower production cost due to reverse engineering and low R&D outlays has been a major factor in keeping the prices under check.

The global pharmaceutical industry is estimated at $ 300 billion, not all representing cross-border trade.  India's measly share of $ 1.5 billion in global trade represents an untapped potential. Under the regime of economic liberalisation underway since early 1990s, the drugs and pharmaceutical sector witnessed initiatives at fresh investment in the sector. Nearly 1735 investment proposals of the order of around Rs 166  billion were initiated. The foreign collaboration proposals approved numbered around 425 with a foreign direct investment  (FDI) component of over Rs 25 billion. The pharmaceuticals have figured high on the export front. In 2001-02,  the sector was  estimated to have registered a growth of 17.6% at around Rs 20.3 billion.

In the wake of economic liberalisation, many a  overseas players  returned or contemplated returning to India. These include Ivox Corp (USA),  Taro Pharmaceuticals (Israel) and Merck (USA). These are out either to set shop or looking for acquisitions in India. Hexal AG of Germany has established a liaison office in India. MILLIONCs like Rocha, Bayer, Aventis and Chiron are making India a regional hub for bulk drugs. 

The Export Import Bank of India (Exim Bank) had  doubled its corpus for the pharmaceutical industry to Rs 2 billion as a result of increased activity in the industry, especially in the external sector. The fund is used for the development and commercialisation of the new products and applications, significant improvement in the existing design of  products, setting up and expansion of pilot plants, research studies for obtaining regulatory approvals, cost of filing and managing international patent and R&D Centres.

It needs, however, to be recognised that the presence  of small scale manufacturers has resulted, on the one hand,  in a highly fragmented industry, and on the other, it has made it possible to supply a near 100,000 drugs including vitamins, antibiotics, antibacterials, cardio-vascular and other essential drugs. These account for nearly 37% of the market.  While each of about 80% of the manufacturers has annual sales below a billion rupees, top ten companies are known to control over 30% of the market. At present there are more than 20,000 players in the country.

The major players are: Alembic Chem, Aurobindo Pharma, Cipla, Dr. Reddy's, FDC, IPCA Labs, Jagsonpal Pharma, J.B. Chemicals, Kopran, Lupin Labs, Lyka Labs, Morepan Labs, Nicholas Piramal, Ranbaxy Labs, Sun Pharma, Themis Medicare, GlaxoSmithkline, Astrazeneca, Aventis, E-Merck, Torrent Pharma, TTK Healthcare, Unichem Labs,  Wockhardt  and  Zandu Pharma.  Until recently, only a few of the Indian companies had gone into any serious R&D activity. Much of the effort was directed to affordable analogue research. The R&D level in the country is low with even well-placed pharma companies spending less than 2% of turnover on R&D. MILLIONCs are known to contribute as much as 10% or more of their turnover to R&D.  While India is very strong in process chemistry, biology and applied bio-chemistry, initiatives at all levels - government, academia, private sector - involving heavy financial outlays, are called for.

Ayurveda continues to remain a preferred system of medicine for a vast segment of population in the country. The country has over 400,000 registered practitioners of the Indian system of medicine. Around 170 institutes properly affiliated to various universities impart under- or post-graduate courses each year. These institutes churn out some 5,500 fresh practitioners. The practitioners are supported by 12,000 dispensaries and 2,100 beds available for ayurveda treatment countrywide. The emerging biotechnology sector has already taken by storm and is offering sops to states to make these as the thriving ground for the highly potential segment in medicare.

How to Prepare Project Report on Pharmaceutical Processing Industry?

Drug manufacturing companies work under strict laws and regulations. Their processes need to comply with relevant drugs act in their respective countries.

Therefore, if you are planning to invest in pharmaceutical processing, a good project report will be necessary. Besides the prominent aspects of a project report, you should pay close attention to the following issues in a pharmaceutical processing report.

1. Marketing

This industry is very competitive. I need not stress the value of detailed market analysis. You need to understand the status of market competition and the demand for pharmaceutical products. A proper market analysis will additionally help you prepare an excellent pharmaceutical business plan. Given your market analysis report, you will develop a marketing plan.

2. Government approval

In almost all countries, there are laws and regulations for the manufacture, distribution, and administration of drugs. Consider giving a status report on these requirements when making the final project status report.

3. Manufacturing Process

It would help if you had a picture of the process you will employ in making your drugs. Outline the quality checks and balances in the process. State the required pharmaceutical intermediates and their corresponding active pharmaceutical ingredients.

4. Machines and Equipment

You need to identify the equipment you will need, such as homogenizers, spectrophotometer, tabulating machines, etc. to ensure the machines meet quality specifications. You may also need to put down a plan to train workers on their operations.

How Does the Drug Manufacturing Process Work?

If you are an aspiring drug manufacturer, you should know how the bulk drug manufacturing process works. This is a complicated process and requires professional skills in molecular biology, medical microbiology, and pharmacy.

The process involves four steps, namely:

  • Milling
  • Granulation
  • Coating
  • Tabulation

Milling is important because it makes the drug powder uniform. It ensures uniform distribution of the active pharmaceutical ingredients. Additionally, milling makes it easier to formulate the drug into a syrup or emulsion.

After milling, you can use wet or dry granulation to form granules. You then coat them and compress the drugs using a tabulating machine. Alternatively, you can fill the granules into capsules.

For any chemical industry business ideas, prioritize the security of your staff. Ensure workers have sufficient PPEs. Have plans to protect them from chemical poisoning. Install eyewashes and emergency showers in both production units and laboratories.

Pre-Feasibility Report on Bulk Drug Manufacturing Process

Before you set up a feasibility report or start making a business plan, you first need to do a pre-feasibility study. It is the conclusions of this study that will make you decide whether to proceed to the project feasibility report or not.

Implementing a pharmacy business plan is an expensive affair. Please do not put any investment into a business plan of this magnitude without looking at its feasibility study report.

Considering the variety of pharmaceutical products, a feasibility plan will help you decide on the most relevant product for your target market. The results of pre-feasibility and feasibility studies will inform your marketing strategy plan. At the pre-feasibility stage, you get to review the technical skills required for the bulk drug manufacturing process. You also assess the knowledge level and determine whether you have the knowledge and skills.

Lastly, this report looks at the financial demands of a chemical project report on bulk drug processing. From here, you will decide on the feasibility of the project.

How to Grow Pharmaceutical Intermediates Market?

The pharmaceutical industry relies on pharmaceutical intermediates. We use these chemicals to produce active pharmaceutical ingredients (API). 

To grow the pharmaceutical intermediates market, therefore, we should focus on the drug manufacturing industry. Here are some tips on how we can grow this industry.

1. Investment in Research and Development

We should encourage governments and established drug manufacturers to invest in research and development of new medicines. New drug development will increase the need for pharmaceutical intermediates. Consequently, this will cause the growth of the industry.

2. Boost Generic Drug Manufacturing

Feasibility study reports for project ideas in pharmaceuticals show a growing demand for generics. This demand is particularly high in developing countries. More investment in generic drugs will result in increased demand for pharmaceutical intermediates.

3. Collaborations

It is quite expensive to run a pharmaceutical intermediate processing company. If you look at a project summary example for the local industry and you will notice the huge investment. One way of cushioning the industry is to encourage collaborations, mergers, and acquisitions. Working together gives small-scale companies a competitive advantage. It lowers their operation costs and improves revenue.

How to Set Up a Chemical Industry Business Plan?

Writing a chemical industry business plan begins with a pre-feasibility study. Here, you look at the various business ideas in chemical manufacturing. You then evaluate each of these ideas based on:

1. Skills and Knowledge

If you are interested in the chemical manufacturing industry, I assume that you have some skills or knowledge in this sector. If so, look at the skills required for each idea you have. Which of these ideas marches your skills and knowledge?

2. Financial Resources

Different chemical processes have different cost implications. Try to review each idea against the expected financial input. You can examine some business plan examples on the internet to get a hint on required inputs. Once you have a convincing pre-feasibility report, you can proceed to make a feasibility report meaning the idea is profitable and viable.

The next step in setting up a chemical industry business plan is to prepare a small business marketing plan. The results of your feasibility report will help do this.

Chemical manufacturing is not only expensive, but it is also strictly regulated by law. It would be best if you had an innovative marketing strategy to break even. It would be best if you did an accurate market analysis.

A project report on the pharmaceutical industry helps you assess the dynamics of the industry. You will want to know who the major chemical manufacturers are. You will also assess the availability of raw materials and machinery for your pharmaceutical industry.

In your project report, you will also address the technical aspects of the pharmaceutical manufacturing process. You need to draw a flow diagram for the process. Lastly, sit down and draw a business plan for your chemical industry business. You will need the information from all the above processes. Additionally, a business plan will consider the financial implications of your pharmaceutical industry project report.


We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 22 of 25 | Total 244 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 22 24 25   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

IV Fluids (BFS Technology)

Fluids are given when someone's body fluid volume falls. There are a number of things which can cause a drop in fluid volume. Vomiting and diarrhea are a classic example, which is why people are encouraged to drink fluids when they are sick, to keep their fluid volume stable. Another cause is blood loss, which causes problems both because people lose blood products, and because they experience a loss in fluid volume. Electrolyte levels in the blood can also become unstable as a result of rapid changes in fluid volume, in which case intravenous fluids can be used to restore the balance. Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. These fluids must be sterile to protect patients from injury, and there are a number of different types available for use. Many companies manufacture packaged intravenous fluids, as well as products which can be mixed with sterile water to prepare a solution for intravenous administration. The global Intravenous (IV) solutions market was valued at USD 6.9 billion in 2015 and is projected to grow at a CAGR of 7.8% over the forecast period. The emergence of this market is attributed to the fast growing geriatric population and prevalence of malnutrition in the elderly and pediatric population. Intravenous (IV) solutions are fluids which are intended to be administered to a patient directly into the venous circulation. These fluids are sterile fluids which protects patients at the time of serious dehydration. There is various type of IV solutions available for use in the market. Many companies manufacture packaged intravenous fluids or products or compounds which can be mixed with sterile water to prepare a solution for intravenous administration. The market for Intravenous (IV) Solution is expected to reach USD 11,511.2 million by 2022 and is expected to grow at a CAGR of 7.69% during the forecast period 2016-2022. The factors which drive the growth of the market are the rising prevalence of chronic diseases, rising acceptance of vitamin C intravenous treatment therapy to treat colorectal cancer. This is attributed to the factors such as Growing acceptance of vitamin C intravenous for Colorectal Cancer and increasing prevalence of the chronic diseases. Europe is the second largest market which is growing at a CAGR of 8.12% from 2016-2022. Asia-Pacific region is the fastest growing market for IV Solutions, which is expected to grow at a CAGR of 8.34% during the forecast period from 2016 to 2022. Few Indian major players are as under Shree Krishna Keshav Laboratories Ltd. Pharmazell (India) Pvt. Ltd. Parenteral Surgicals Ltd. Kokad Pharmaceutical Laboratories Ltd. Ahlcon Parenterals (India) Ltd. Abaris Healthcare Pvt. Ltd. Axa Parenterals Ltd.
Plant capacity: IV Fluids (500 ml Size Pack): 146,748 Units / Day IV Fluids (100 ml Size Pack): 153,252 Units / DayPlant & machinery: Rs 4099 lakhs
Working capital: -T.C.I: Cost of Project : Rs 5808 lakhs
Return: 25.00%Break even: 41.00%
Add to Inquiry Add to Inquiry Basket

Toothpaste

Toothpaste is a paste or gel to be used with a toothbrush to maintain and improve oral health and aesthetics. Since their introduction several thousand years ago, toothpaste formulations have evolved considerably - from suspensions of crushed egg shells or ashes to complex formulations with often more than 20 ingredients. Among these can be compounds to combat dental caries, gum disease, malodor, calculus, erosion and dentin hypersensitivity. Furthermore, toothpastes contain abrasives to clean and whiten teeth, flavors for the purpose of breathe freshening and dyes for better visual appeal. Effective toothpastes are those that are formulated for maximum bioavailability of their actives. This, however, can be challenging as compromises will have to be made when several different actives are formulated in one phase. Toothpaste development is by no means complete as many challenges and especially the poor oral substantively of most active ingredients are yet to overcome. The global toothpaste market is projected to grow at a CAGR of 6.1% during the forecast period. The toothpaste market was valued at USD 26.09 billion in 2018, and it is projected to reach USD 36.98 billion by 2024. Increasing dental problems among children and adults, due to poor eating habits, and the rise in popularity for herbal oral care products are the factors primarily driving the global toothpaste market. The rapidly changing lifestyle, improper diet, including sugar-rich diets, and the increased consumption of alcohol and tobacco have made oral health one of the major public health problems in almost every part of the world. The impact of oral diseases on people's everyday lives is subtle and pervasive, influencing food habits, sleep, rest, social roles, and almost every phase of the day. Collectively, oral diseases and disorders create substantial pain and suffering. Owing to this, consumers across the world have started paying immense attention to maintaining their oral health, which has led to an increase in the sales of toothpaste across the world. Thus, due to demand it is best to invest in this project.
Plant capacity: Toothpaste 35 gms Tubes : 28,572 Tubes / Day Toothpaste 70 gms Tubes: 14,286 Tubes / Day Toothpaste 140 gms Tubes: 7,143 Tubes / DayPlant & machinery: Rs 173 lakhs
Working capital: -T.C.I: Cost of Project: Rs 2185 lakhs
Return: 22.00%Break even: 44.00%
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac sodium • Acecloflenac

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. The Asia Pacific is expected to emerge as the fastest-growing regional market due to rapidly increasing the prevalence of therapeutic and chronic diseases i.e., diabetes, cancer etc. with rising population in this region. According to WHO, around 65% of all cancer deaths occur in developing countries and the number of global cancer deaths is projected to increase by 45 percent from 2007 to 2030 with from 7.9 million to 11.5 million deaths influenced by rise in consumption of tobacco use, unhealthy diet, insufficient physical activity and the harmful use of alcohol in this region. The active pharmaceutical ingredients market gets a major boost from the growing prevalence of cardiovascular conditions, infectious diseases, and various other chronic disorders. Other than these, the rise in various genetic disorders has driven the use of biologicals and biosimilars, the world over. In many instances, biosimilars are the most preferred owing to them being low-cost. Biosimilars have the potential of creating a highly sustainable healthcare system which makes way for innovation, allowing more patients to receive the optimum care. Thus, due to demand it is best to invest in this project. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Sanofi India Ltd. Piramal Enterprises Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.
Plant capacity: Azithromycin: 500 Kgs / Day Cefixime: 500 Kgs / Day Telmisartan: 50 Kgs / Day Diclofenac Sodium: 500 Kgs / Day Aceclofenac: 500 Kgs / DayPlant & machinery: Rs 155 lakhs
Working capital: -T.C.I: Cost of Project : Rs 729 lakhs
Return: 31.00%Break even: 61.00%
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac sodium • Acecloflenac

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. The Asia Pacific is expected to emerge as the fastest-growing regional market due to rapidly increasing the prevalence of therapeutic and chronic diseases i.e., diabetes, cancer etc. with rising population in this region. According to WHO, around 65% of all cancer deaths occur in developing countries and the number of global cancer deaths is projected to increase by 45 percent from 2007 to 2030 with from 7.9 million to 11.5 million deaths influenced by rise in consumption of tobacco use, unhealthy diet, insufficient physical activity and the harmful use of alcohol in this region. The active pharmaceutical ingredients market gets a major boost from the growing prevalence of cardiovascular conditions, infectious diseases, and various other chronic disorders. Other than these, the rise in various genetic disorders has driven the use of biologicals and biosimilars, the world over. In many instances, biosimilars are the most preferred owing to them being low-cost. Biosimilars have the potential of creating a highly sustainable healthcare system which makes way for innovation, allowing more patients to receive the optimum care. Thus, due to demand it is best to invest in this project. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Sanofi India Ltd. Piramal Enterprises Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.
Plant capacity: Azithromycin: 500 Kgs / Day Cefixime: 500 Kgs / Day Telmisartan: 50 Kgs / Day Diclofenac Sodium: 500 Kgs / Day Aceclofenac: 500 Kgs / DayPlant & machinery: Rs 155 lakhs
Working capital: -T.C.I: Cost of Project : Rs 729 lakhs
Return: 31.00%Break even: 61.00%
Add to Inquiry Add to Inquiry Basket

Sterile Water for Injection

Sterilization is a term referring to any process that eliminates (removes) or kills all forms of microbial life, including transmissible agents (such as fungi, bacteria, viruses, spore forms, etc.) present on a surface, contained in a fluid, in medication, or in a compound such as biological culture media. Sterilization can be achieved by applying the proper combinations of heat, chemicals, irradiation, high pressure, and filtration. Sterile Products are dosage forms of therapeutic agents that are free of viable microorganisms. Principally these include Parenteral, ophthalmic and irrigating preparations. Of these, Parenteral preparations are unique among dosage forms because they are injected through skin or mucous membranes into internal body compartments. The parenteral range of drug administration is important in treating medical emergencies in which a subject is comatose or cannot swallow and in providing various types of maintenance therapy for hospitalized patients. Injectables circumvent the highly efficient first line of body defence, the skin and mucous membranes. They must therefore be free from toxic components and so, must possess purity of a very high order. Hence, they are made sterile before use. Sterile products are most frequently solution or suspensions, but may even be solid pellets for tissue implementation. The manufacturing of parenterals has become a highly specialized area in pharmaceutical processing. The rising number of surgeries, the need for a faster route of drug administration, growing preference for single-dose administration of vaccines and drugs, and an increase in local manufacturing is expected to drive the market for LVP. Parenteral route of administration helps provide an accurate dose of medication as the majority of the drug is directly absorbed in circulation, bypassing the gastrointestinal tract. Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025. Pharmaceuticals export from India stood at US$ 20.70 billion in FY20. Pharmaceutical export include bulk drugs, intermediates, drug formulations, biological, Ayush and herbal products and surgical. India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected grow at an average growth rate of around 30 per cent a y-o-y to reach US$ 100 billion by 2025. Entrepreneurs who invest in this project will be successful. Few Indian major players are as under Medipol Pharmaceutical India Pvt. Ltd. Maan Pharmaceuticals Ltd. Ivy Health & Life Sciences Pvt. Ltd. Parenteral Drugs (India) Ltd. Pharmaceutical Products Of India Ltd. Shree Krishna Keshav Laboratories Ltd. Pharmaids Pharmaceuticals Ltd.
Plant capacity: Ampoules 5 ml Size: 200,000 Nos. / Day Ampoules 10 ml Size: 150,000 Nos. / Day Ampoules 20 ml Size: 150,000 Nos. / DayPlant & machinery: Rs 1933 lakhs
Working capital: -T.C.I: Cost of Project : Rs 3040 lakhs
Return: 27.00%Break even: 39.00%
Add to Inquiry Add to Inquiry Basket

7-Aminocephalosporanic Acid (7-ACA)

Cephalosporins, a large group of ?-lactam antibiotics, contain a 7-aminocephalosporanic acid (7-ACA) nucleus which is derived from cephalosporin C, and substitutions of chemical groups or modifications of 7-ACA side-chains resulting in varying pharmacologic properties and antimicrobial activities, development of useful antibiotic agents, also. Cephalosporin C obtained by fungus fermentation can be transformed to 7-ACA by two-step or one step enzymatically conversion process. The most important step in 7-ACA downstream process is represented by its separation from enzymatically produced reaction mixture. Among the used methods new separation techniques have been developed and applied to bioseparations, like reactive extraction and pertraction which have considerable potential. 7-aminocephalosporanic acid is abbreviated as 7-ACA, white or almost white crystalline powder, 7-ACA is an important nucleus in synthesis of cephalosporin antibiotics, in the nucleus 7 and 3 chemical transformation can be used to prepare many cephalosporins: cefazolin sodium, cefotaxime sodium, ceftriaxone sodium, cefoperazone sodium, sodium ceftazidime, cefuroxime sodium. 7-Aminocephalosporanic Acid [chemically, 3-(Acetyloxy-methyl)-7-amino- 8-oxo-5-thia-1- azabicyclo (4.2.0) oct-2-ene-2-carboxylic acid] is the active nucleus for the synthesis of cephalosporins and intermediates. 7-ACA affect the antibacterial activity and can lead to the alteration of pharmacokinetic properties and receptor binding affinity, thus creating new class of cephalosporin antibiotics with important clinical uses. API market based on synthesis is further divided into synthetic API, Biotech API and HPAPI. Synthetic API holds major share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. The major factors driving the synthetic chemical API market are patent expiration of synthetic (small molecule drugs), increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in incidence of chronic and age-related diseases, rapid growth in oncology market, technological advancement like cryogenic and continuous flow manufacturing. Based on the customer, the synthetic API is further divided into branded API and generic API. Branded API accounted the largest share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. Generic API is expected to grow at a high single digit CAGR from 2018 to 2025, due to Patent expiry of blockbuster drugs, rising healthcare expenses, increasing outsourcing and shift towards the generic medicines led by the government initiatives. Entrepreneurs who invest in this project will be successful.
Plant capacity: 7-Aminocephalosporanic Acid: 2 MT / DayPlant & machinery: Rs 1791 lakhs
Working capital: -T.C.I: Cost of Project : Rs 3419 lakhs
Return: 28.00%Break even: 46.00%
Add to Inquiry Add to Inquiry Basket

Herbal Toothpaste

Toothpaste is a paste or gel to be used with a toothbrush to maintain and improve oral health and aesthetics. Since their introduction several thousand years ago, toothpaste formulations have evolved considerably - from suspensions of crushed egg shells or ashes to complex formulations with often more than 20 ingredients. Among these can be compounds to combat dental caries, gum disease, malodor, calculus, erosion and dentin hypersensitivity. Global Herbal Toothpaste Market 2020 is on track to obtain a growth rate of 5.22% between 2019 and 2024. The global herbal toothpaste market has been segmented based on pack size, distribution channel, and region. The global market has been classified, based on pack size, as 25gm, 50 gm, 100gm, and others. The global market has been segmented, based on distribution channel, store-based, and non-store-based. The store-based segment has been further bifurcated into supermarkets & hypermarkets, convenience stores, and others. However, the herbal toothpaste market may benefit from the tariff wars imminent as a result of the Covid-19 crisis, as countries may aim to reduce imports of chemical-based toothpastes that China has taken a lead in, thereby boosting the herbal toothpaste market. The growing intake of tobacco and its rising negative impact on the oral health has driven the sale of easy to go and convenient oral care herbal products worldwide. Renowned firms in the market are taking up several initiatives to promote the sales of herbal toothpastes by spreading awareness about the benefits of these products. They are trying to convince consumers about the high effectiveness of herbal toothpastes in maintaining oral health and dental hygiene. Entrepreneurs who invest in this project will be successful. Few Indian major players are as under Colgate-Palmolive (India) Ltd. Dabur India Ltd. Herbalife International India Pvt. Ltd. Organic India Pvt. Ltd. Vicco Products (Bombay) Pvt. Ltd. Patanjali Ayurved Ltd.
Plant capacity: Herbal Toothpaste 30 gms Size Tubes: 32,000 Tubes / Day Herbal Toothpaste 80 gms Size Tubes: 12,000 Tubes / DayPlant & machinery: Rs 83 lakhs
Working capital: -T.C.I: Cost of Project : Rs 812 lakhs
Return: 34.00%Break even: 40.00%
Add to Inquiry Add to Inquiry Basket

Toothpaste

Toothpaste is a paste or gel to be used with a toothbrush to maintain and improve oral health and aesthetics. Since their introduction several thousand years ago, toothpaste formulations have evolved considerably - from suspensions of crushed egg shells or ashes to complex formulations with often more than 20 ingredients. Among these can be compounds to combat dental caries, gum disease, malodor, calculus, erosion and dentin hypersensitivity. Furthermore, toothpastes contain abrasives to clean and whiten teeth, flavors for the purpose of breathe freshening and dyes for better visual appeal. Effective toothpastes are those that are formulated for maximum bioavailability of their actives. This, however, can be challenging as compromises will have to be made when several different actives are formulated in one phase. Toothpaste development is by no means complete as many challenges and especially the poor oral substantively of most active ingredients are yet to overcome. The global toothpaste market is projected to grow at a CAGR of 6.1% during the forecast period. The toothpaste market was valued at USD 26.09 billion in 2018, and it is projected to reach USD 36.98 billion by 2024. Increasing dental problems among children and adults, due to poor eating habits, and the rise in popularity for herbal oral care products are the factors primarily driving the global toothpaste market. Moreover, rising premiumization and consumers seeking more targeted solutions are accelerating the growth of the market studied. The rise in consciousness of oral health has helped vendors introduce oral hygiene product categories, such as teeth-whitening products. One of the popular products used for teeth whitening is whitening toothpaste. Manufacturers offer toothpaste with teeth-whitening functionality that differs from ordinary toothpaste. To improve market position, manufacturers are constantly focusing on implementing innovative strategies and introducing a broad portfolio of products. Entrepreneurs who invest in this project will be successful.
Plant capacity: White Toothpaste 50 gms Size: 96,000 Tubes / Day White Toothpaste 240 gms Size: 16,800 Tubes / Day Striped Toothpaste 180 gms Size: 33,600 Tubes / Day Gel Toothpaste 120 gms Size: 67,200 Tubes / DayPlant & machinery: Rs 308 lakhs
Working capital: -T.C.I: Cost of Project : Rs 6936 lakhs
Return: 36.00%Break even: 34.00%
Add to Inquiry Add to Inquiry Basket

Disposable Nitrile Gloves (Powder Free)

Nitrile gloves are a type of disposable gloves made from synthetic rubber, this means there is no risk of latex allergies. They are the most popular gloves type in our range and offer superior strength, dexterity and resistance to oils and aqueous chemicals in comparison to vinyl or latex. For these reasons, they are often used in the medical, laboratory and manufacturing industries. Nitrile gloves are the perfect compromise between latex and vinyl. Nitrile is made from an allergy safe compound that feels a lot like latex but it’s much stronger, costs less, and is more comfortable to wear. Nitrile is perfect for demanding applications, especially cleaning and dishwashing. Our lightly powdered versions are produced with a food grade corn starch powder, making it easier to take them on or off – especially with wet hands. Powder free gloves go through an extra process of chlorinating the gloves to ease donning. The Global Rubber Gloves market is expected to grow at a CAGR of 8.5% between 2014 and 2022. The factors such as rising healthcare expenditure, increasing health threats and increasing hygiene awareness and healthcare regulations are driving the market growth. The global demand for gloves remained robust and would continue even in times of recession, adding that most players had moved into producing Nitrile gloves in line with the current market demand. Indian glove market is growing at 15% while the demand for examination gloves has been rising by 20%per annum. St Mary’s is the largest supplier of centrifugal latex under the brand Cenex, a crucial raw material for manufacturing rubber dipped goods like gloves, balloons, condoms and rubber bands. Indian glove market is growing at 15 per cent while the demand for examination gloves has been rising by 20 per cent per annum. St Mary’s is the largest supplier of centrifugal latex under the brand Cenex, a crucial raw material for manufacturing rubber dipped goods like gloves, balloons, condoms and rubber bands. “The glove industry has become very innovative and has gone into technological transformation. Nonetheless, we need the support of the Government to facilitate the transformation. Innovation comes from talent and hence people skills. With the right talent pool, the industry is set to see better prospects in the years ahead. Thus, due to demand it is best to invest in this project. Few Indian major players are as under Honeywell International (India) Pvt. Ltd. London Rubber India Ltd. Mallcom (India) Ltd. Narang Medical Ltd. Sara Healthcare Pvt. Ltd. Wellness Forever Medicare Pvt. Ltd.
Plant capacity: Disposable Nitrile Gloves (Powder Free): 500,000 Pcs. / DayPlant & machinery: Rs 1321 lakhs
Working capital: -T.C.I: Cost of Project : Rs 2890 lakhs
Return: 30.00%Break even: 45.00%
Add to Inquiry Add to Inquiry Basket

Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Acecloflenac Manufacturing. Production of Active Pharma Ingredients (API).

Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Acecloflenac Manufacturing. Production of Active Pharma Ingredients (API). Opportunities for Entrepreneurs to Start Own Industry. The active pharmaceutical ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. Related Project: - Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac Sodium • Acecloflenac Active Pharmaceutical Ingredient (API) is the portion of drug that generates intentional effects. APIs are biologically and chemically active constituents of medicines with direct effect in mitigation, prevention, cure and treatment of diseases. Some of the medicines like combination therapies have many active ingredients to treat diverse symptoms or perform in numerous ways. Active Pharmaceutical Ingredient has active ingredient that is contained in medicine. For illustration, an active ingredient to reduce pain is incorporated in a painkiller. A slight amount of the active ingredient has result thus only small part of the active ingredient is confined in medicine. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Market Outlook Active Pharmaceutical Ingredients Market Dynamics The growing cases of chronic diseases are one of the leading causes of hospitalization, and a majority of the patients with these conditions may need re-admission in hospitals due to infection leading to other chronic diseases. For instance, according to the report published by the Centers for Disease Control and Prevention (CDC), nearly 92.1 million adults in the US dealt with at least one type of cardiovascular disease in 2017. Besides, CDC has also stated that out of the total annual healthcare expenditure, i.e., USD 27 trillion, 86% is for the people with chronic health conditions in the US. Some of the prime factors spurring the growth of the market are increasing occurrences of cardiovascular, oncology, lifestyle and diabetes diseases, intensifying number of diagnostic centers and hospitals and escalating elderly population in emerging countries. Furthermore, cumulative healthcare spending, growing disease responsiveness and education are propelling the growth of the market. Related Projects: - Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing With advancements in healthcare infrastructure, healthcare spending has increased over time. This augmenting focus on healthcare spending positively influences the market for active pharmaceutical ingredients. The high adoption rate of generic drugs in developed and developing economies is fueling the growth of the market. Another positive impact comes from the high demand for specialty medicines which is anticipated to escalate the spending in the pharmaceutical sector. Developed nations are expected to exhibit faster growth in these spending as compared to the developing economies on the back of factors such as the presence of adequate manufacturing units, transparent pricing, and higher spending power. Specialty medicines a trend in the active pharmaceutical ingredients market A higher generic adoption rate in developed countries that ranges from 27% to 32% is driving global medicine spending and aiding greater access to improved, lifesaving healthcare services. The adoption of branded generic drugs is predicted to be higher in emerging economies such as China and India and generic drugs accounted for nearly 80% of the total drugs sold by value in these fast-growing nations in 2016. Rising use of specialty medicines is anticipated to grow the pharmaceutical spending worldwide with quicker growth in richer, developed nations as compared to their emerging counterparts. This is primarily because the former have adequate manufacturing units, a higher spending power, and greater emphasis on transparent pricing by assessing measuring effects on the population. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Active pharmaceutical ingredient (API), is the term that is used to refer to the biologically active component of a drug (e.g. tablet, capsule). A drug is usually composed of several components. The API represents the primary ingredient. Other ingredients are commonly known as "excipients. Sometimes a drug can contain several APIs and its effect on a patient depends on the dosage prescribed and can vary from person to person. In combination therapies, two or more than two active ingredients are used to treat different symptoms in different ways. Stringent quality control is a mandate when it comes to the manufacturing of drugs as the API represents the main component considered while making the prescription. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs. Key Players:- Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. Tags: - #APIBusiness #apimanufacturing #Apiproduction #APImarket #APIProject #ApiStartup #APIindustry #Activepharmaingredients #pharmaingredients #IndianPharma, #medicineingredients #CoronavirusBusiness #COVID2019 #Activepharmaingredientbusinessplan #APIbusinessplan #APIbusinessidea #startupAPIbusiness #Activepharmaingredientmanufacturing #APIproduction #API #Azithromycin #Cefixime #Telmisartan #Diclofenacsodium #Acecloflenac #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #entrepreneurindia #startupbusiness #startupbusinessideas #howtostartbusiness #InvestInStartups #Plan4Business #StartupProject #ProjectReport #startupplan #BusinessKaiseshurukare #BusinessProjectReport
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 22 of 25 | Total 244 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 22 24 25   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top